Immuneering-logo (1).png
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024 08:00 ET | Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
logo (1).png
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
March 27, 2024 02:30 ET | Vidac Pharma Holding PLC
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Immuneering-logo (1).png
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024 08:00 ET | Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
Imugen.PNG
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
February 22, 2024 10:10 ET | Imugene Limited
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
Vidac Pharma présent
Vidac Pharma présente une efficacité élevée dans plusieurs modèles de tumeurs solides pour son candidat médicament anticancéreux de nouvelle génération, et une synergie avec le traitement standard des organoïdes du cancer du foie
February 19, 2024 01:30 ET | Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 février 2024, 7:30 CET – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ) est une société biopharmaceutique d'oncologie de stade...
Vidac Pharma present
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids
February 19, 2024 01:30 ET | Vidac Pharma Holding PLC
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
November 07, 2023 08:30 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...
Kura Oncology Logo
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
November 02, 2023 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Elucida Oncology Logo.jpg
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET | Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
apeiron_logo.jpg
GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers
October 17, 2023 07:00 ET | GT Apeiron LLC
GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor